Response evaluation
DISEASE
Patients underwent disease staging at baseline, after courses 2 and 4 and then every four courses thereafter. The primary endpoint for response analysis is the BOR, defined as the best response observed before progression or start of another therapy. All eligible patients who receive any amount of lorlatinib were considered evaluable for response unless deemed by the SMC to have inadequate imaging to assess overall response. Response was graded according to the NANT response criteria version 2.0 (ref. 